Ron Philip has served on our board of directors since April 2025. Mr. Philip has served as Chief Executive Officer and as a member of the board of directors of Orbital Therapeutics, a biotech company focused on the development of RNA-based medicines, from September 2024 until its acquisition by Bristol-Myers Squibb in December 2025. Prior to Orbital, from May 2017 to September 2024, Mr. Philip served in several roles for Spark Therapeutics, a gene therapy company, most recently as Chief Executive Officer. Mr. Philip also served in various roles for Pfizer from November 2009 to October 2016. Mr. Philip has also previously served on the boards of several private organizations, including the Academy of Natural Sciences of Drexel University, Cure Duchenne and the Chamber of Commerce for Greater Philadelphia. Mr. Philip received a B.S. in Computer Information Systems from Drexel University. We believe that Mr. Philip is qualified to serve on our Board because of his extensive experience in the life sciences industry developing and leading teams focused on novel treatments, as well as his demonstrated business acumen.